000181501 001__ 181501
000181501 005__ 20230208173454.0
000181501 0247_ $$2CORDIS$$aG:(EU-Grant)680997$$d680997
000181501 0247_ $$2CORDIS$$aG:(EU-Call)H2020-HCO-2015$$dH2020-HCO-2015
000181501 0247_ $$2originalID$$acorda__h2020::680997
000181501 035__ $$aG:(EU-Grant)680997
000181501 150__ $$aFree Respiratory Evaluation and Smoke-exposure reductionby primary Health cAre Integrated gRoups$$y2015-10-01 - 2018-09-30
000181501 371__ $$aINTERNATIONAL PRIMARY CARE RESPIRATORY GROUP LBG$$bIPCRG$$dUnited Kingdom$$ehttp://www.theipcrg.org$$vCORDIS
000181501 371__ $$aACADEMISCH ZIEKENHUIS GRONINGEN$$bUNIVERSITAIR MEDISCH CENTRUM GRONINGEN$$dNetherlands$$ehttp://www.umcg.nl$$vCORDIS
000181501 371__ $$aMINISTERSTVO ZDRAVOOHRANENIYA KYRGYZSKOY RESPUBLIKI$$bMINISTRY OF HEALTH KYRGYZ REPUBLIC$$dKyrgyzstan$$ehttp://www.med.kg$$vCORDIS
000181501 371__ $$aEUROPEAN COPD COALITION$$dBelgium$$ehttp://www.copdcoalition.eu$$vCORDIS
000181501 371__ $$aARTEG BV$$dNetherlands$$vCORDIS
000181501 371__ $$aTRUONG DAI HOC Y DUOC TP.HCM$$bUNIVERSITY OF MEDICINE AND PHARMACY AT HOCHI MINH CITY$$dViet Nam$$vCORDIS
000181501 371__ $$aWashington University in St. Louis$$bWUSTL$$dUnited States$$ehttp://wustl.edu/$$vCORDIS
000181501 371__ $$aEUROPEAN LUNG FOUNDATION$$dUnited Kingdom$$ehttp://www.european-lung-foundation.org$$vCORDIS
000181501 371__ $$aPANEPISTIMIO KRITIS$$bUNIVERSITY OF CRETE$$dGreece$$ehttp://www.uoc.gr$$vCORDIS
000181501 371__ $$aNCSCT COMMUNITY INTEREST COMPANY$$dUnited Kingdom$$ehttp://www.ncsct.co.uk$$vCORDIS
000181501 371__ $$aIT University of Copenhagen$$bIT University of Copenhagen$$dDenmark$$ehttp://en.itu.dk/$$vCORDIS
000181501 371__ $$aPlymouth University$$bPlymouth University$$dUnited Kingdom$$ehttps://www.plymouth.ac.uk/$$vCORDIS
000181501 371__ $$aREGION HOVEDSTADEN$$bREGIONH$$dDenmark$$ehttp://www.regionh.dk$$vCORDIS
000181501 371__ $$aACADEMISCH ZIEKENHUIS LEIDEN$$bLeiden University Medical Center$$dNetherlands$$ehttp://www.lumc.nl$$vCORDIS
000181501 371__ $$aMakerere University$$bMakerere University$$dUganda$$ehttp://mak.ac.ug/$$vCORDIS
000181501 372__ $$aH2020-HCO-2015$$s2015-10-01$$t2018-09-30
000181501 450__ $$aFRESH AIR$$wd$$y2015-10-01 - 2018-09-30
000181501 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000181501 680__ $$aFRESH AIR is a 3 year project which addresses the urgent need to prevent, diagnose and treat lung diseases in LMICs and other low-resource settings where the greatest burden of disease is experienced. Our Consortium brings together leading international respiratory researchers, clinicians and policy experts from EU member states and the US who have expertise and experience of the challenges of implementation in LMICs and healthcare providers, policy makers and implementers from four countries that represent very different low-resource settings.  

Members will work together to adapt and test innovation and evidence-based practice in the prevention, diagnosis and treatment of lung disease in four low-resource settings in Uganda, Kyrgyz Republic, Vietnam and Greece with high levels of tobacco consumption and exposure to Household Air Pollution (HAP). In so doing, the Consortium will transfer skills and technology from EU member states and the US to new contexts and explore a range of implementation science research questions. The new knowledge this generates will be widely disseminated nationally, regionally and internationally, ensuring the scale-up of interventions tested by the project and global impact of research findings.  The project will also provide new perspectives on policy issues of concern to EU members, increase the international profile of EU funded research on key health challenges and open up markets for healthcare innovations. 

The project has 7 specific objectives focused on the following:

1. Identifying factors influencing the implementation of evidenced-based interventions
2. Exploring which awareness-raising approaches are most effective in achieving behaviour change
3. Adapting interventions that provide smoking cessation support
4. Testing innovative diagnostic methods for COPD
5. Promoting pulmonary rehabilitation as a low cost treatment
6. Reducing children’s risk of lung damage
7. Generating new knowledge, innovation and scalable models.
000181501 909CO $$ooai:juser.fz-juelich.de:277084$$pauthority$$pauthority:GRANT
000181501 909CO $$ooai:juser.fz-juelich.de:277084
000181501 970__ $$aoai:dnet:corda__h2020::5d8f5f3fcf164283dc395fea2e06a146
000181501 980__ $$aG
000181501 980__ $$aCORDIS
000181501 980__ $$aAUTHORITY